National
Gay Republican seeks to unseat Mass. congressman
Boston Globe poll shows Richard Tisei is ahead of incumbent Congressman John Tierney
Richard Tisei may become the first non-incumbent openly gay Republican elected to the U.S. House of Representatives. (photo courtesy of Tisei)
BOSTON – Massachusetts congressional candidate Richard Tisei remains confident that he will become the first openly gay Republican elected to Congress next month.
“I feel pretty comfortable and pretty confident at this point,” Tisei told the Washington Blade during an Oct. 4 interview near Copley Square. A poll the University of New Hampshire Survey Center conducted on behalf of the Boston Globe late last month shows that the former 2010 lieutenant gubernatorial candidate is ahead of incumbent Congressman John Tierney by a 37-31 percent margin.
Thirty percent of respondents said they remain undecided, but the survey further indicates that Tierney’s wife and brothers-in-law’s involvement in an illegal gambling ring has adversely impacted his re-election campaign. “A lot of people in the district are ready for a change and they are looking for a different type of congressman than we have right now. I’ve gotten a great reception from folks.”
Tisei, a former Massachusetts Senate minority leader who co-owns a real estate brokerage company in suburban Lynnfield, announced his candidacy against Tierney last November. He would represent Massachusetts’ Sixth Congressional District that includes portions of Middlesex and Essex Counties north of Boston if elected.
Tierney and the Democratic Congressional Campaign Committee continue to compare Tisei to a Tea Partier in an attack ad currently airing on local television stations. He quickly brushed aside the comparison.
“I’m the only gay, pro-choice Republican who wouldn’t sign the [Grover] Norquist pledge being called an extremist anywhere in the country,” said Tisei. “It’s funny because people who know me find it laughable. I don’t think he’s realized how much he’s damaged his own credibility. Rather than talking about what he’s done over a 16-year period. Trying to paint me as some type of Right Wing extremist is just so off-the-wall that it damages his own credibility.”
He further noted that the economy and jobs are among the top issues on voters’ minds.
“Most of the jobs are created by small business owners who employ 10 or less people and those are the people who don’t feel comfortable or confident hiring anybody right now because there’s so much uncertainty emulating from the government,” said Tisei. “We have a dysfunctional government so nobody knows when the next tax increase is going to be, the next regulation that comes out or how they’re going to be affected. I think a lot of people are just holding back right now hence the reason our economy really hasn’t jump started.”
Tisei would be the first non-incumbent openly gay Republican elected to the House of Representatives. Both former Arizona Congressman Jim Kolbe and former U.S. Rep. Steve Gunderson (R-Wis.) came out after being elected.
GOP establishment continues to back Tisei
Massachusetts Sen. Scott Brown, who volunteered for Tisei’s first state representative campaign in 1984, was among the first prominent Republicans to endorse his campaign. House Speaker John Boehner (R-Ohio,) House Majority Leader Eric Cantor (R-Va.) and the National Republican Congressional Committee have all backed Tisei’s candidacy in spite of their continued support of the Defense of Marriage Act.
“A good number of representatives here in Massachusetts support gay marriage right now and have seen that it’s not the end of the world. And both Democrats and Republicans and the body politic as a whole has evolved,” said Tisei in response to the Blade’s question about how he could spur Capitol Hill Republicans to no longer support DOMA if elected. He further noted he was among the first Massachusetts officials to applaud the state Supreme Judicial Court’s landmark 2003 ruling that struck down the commonwealth’s ban on marriage for same-sex couples.
“Being in Washington, being a member of the caucus, I can help be a catalyst or help bring that process along. I realize that the party as a whole has been a tougher nut to crack, but there are a lot of people within the party who want to see a chance to take place or they want different voices within the party and if an issue like DOMA comes up, somebody like me on the Republican side can stand up and say you know what, this is about fairness, it’s about treating people equally under the law and really appeal to the American ideals to make the argument. If I’m in a position to do that, I think I can change a lot of hearts and minds.”
Tisei, who has also been endorsed by the Victory Fund, further referenced this GOP support to dismiss retiring Massachusetts Congressman Barney Frank’s claims last month that he would be “no use to us in Congress.”
“Barney’s a smart guy, but hearing that argument is so convoluted and most of the people I know within the gay community were baffled by it,” said Tisei. “It’s a bit far-fetched for him to make the argument that he did. I think most normal, rational people can understand that we’ll never have true equality in the country unless you have advocates on both sides of the aisle who are willing to stand up and say, you know what, everybody should be treated fairly.”
Romney “knows how the economy works”
Tisei spoke with the Blade hours after former Massachusetts Gov. Mitt Romney and President Obama squared off in the first presidential debate in Denver.
He noted that he disagreed with Romney on marriage rights for same-sex couples, abortion, stem cell research and other issues. Tisei stressed he feels Romney “knows his stuff as far as what it takes to get companies to create jobs.”
“On economic issues, I think he knows how the economy works,” he said. “I’ve sat with him over the years in a lot of different meeting when he was the governor here and he really does have the knowledge of how the free enterprise system works. Last night he shows he has a depth. People probably see that he could be a good steward of the economy and help jump start the economy.”
Tisei predicted that Brown will ultimately defeat challenger Elizabeth Warren, but he said it will be “a really close election.” He also opposes a federal judge’s decision last month that ordered a taxpayer-funded sex-reassignment surgery for convicted murderer Michelle Kosilek.
“Governor Patrick has come out against this, which should automatically tell people that just how off the charts that decision was,” said Tisei, who sponsored a bill while in the state Senate that would have added gender identity and expression to the commonwealth’s anti-discrimination law. Patrick signed the measure last November. “You’re talking about somebody who murdered another human being. I just don’t think that the state should be doing that.”
A Wider Bridge on Friday announced it will shut down at the end of the month.
The group that “mobilizes the LGBTQ community to fight antisemitism and support Israel and its LGBTQ community” in a letter to supporters said financial challenges prompted the decision.
“After 15 years of building bridges between LGBTQ communities in North America and Israel, A Wider Bridge has made the difficult decision to wind down operations as of Dec. 31, 2025,” it reads.
“This decision comes after challenging financial realities despite our best efforts to secure sustainable funding. We deeply appreciate our supporters and partners who made this work possible.”
Arthur Slepian founded A Wider Bridge in 2010.
The organization in 2016 organized a reception at the National LGBTQ Task Force’s Creating Change Conference in Chicago that was to have featured to Israeli activists. More than 200 people who protested against A Wider Bridge forced the event’s cancellation.
A Wider Bridge in 2024 urged the Capital Pride Alliance and other Pride organizers to ensure Jewish people can safely participate in their events in response to an increase in antisemitic attacks after Hamas militants attacked Israel on Oct. 7, 2023.
The Jewish Telegraphic Agency reported authorities in Vermont late last year charged Ethan Felson, who was A Wider Bridge’s then-executive director, with lewd and lascivious conduct after alleged sexual misconduct against a museum employee. Rabbi Denise Eger succeeded Felson as A Wider Bridge’s interim executive director.
A Wider Bridge in June honored U.S. Rep. Debbie Wasserman Schultz (D-Fla.) at its Pride event that took place at the Capital Jewish Museum in D.C. The event took place 15 days after a gunman killed two Israeli Embassy employees — Yaron Lischinsky and Sarah Milgrim — as they were leaving an event at the museum.
“Though we are winding down, this is not a time to back down. We recognize the deep importance of our mission and work amid attacks on Jewish people and LGBTQ people – and LGBTQ Jews at the intersection,” said A Wider Bridge in its letter. “Our board members remain committed to showing up in their individual capacities to represent queer Jews across diverse spaces — and we know our partners and supporters will continue to do the same.”
Editor’s note: Washington Blade International News Editor Michael K. Lavers traveled to Israel and Palestine with A Wider Bridge in 2016.
The White House
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
President made announcement on Friday
President Donald Trump met with leaders from some of the world’s largest pharmaceutical companies at the White House on Friday to announce his new “Trump Rx” plan and outline efforts to reduce medication costs for Americans.
During the roughly 47-minute meeting in the Roosevelt Room, Trump detailed his administration’s efforts to cut prescription drug prices and make medications more affordable for U.S. patients.
“Starting next year, American drug prices will come down fast, furious, and will soon be among the lowest in the developed world,” Trump said during the meeting. “For decades, Americans have been forced to pay the highest prices in the world for prescription drugs by far … We will get the lowest price of anyone in the world.”
Trump signed an executive order in May directing his administration “to do everything in its power to slash prescription drug prices for Americans while getting other countries to pay more.”
“This represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,” he added.
Several pharmaceutical executives stood behind the president during the announcement, including Sanofi CEO Paul Hudson, Novartis CEO Vas Narasimhan, Genentech CEO Ashley Magargee, Boehringer Ingelheim (USA) CEO Jean-Michel Boers, Gilead Sciences CEO Dan O’Day, Bristol Myers Squibb General Counsel Cari Gallman, GSK CEO Emma Walmsley, Merck CEO Robert Davis, and Amgen Executive Vice President Peter Griffith.
Also in attendance were Health and Human Services Secretary Robert F. Kennedy Jr., Commerce Secretary Howard Lutnick, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, and Food and Drug Administration Commissioner Marty Makary.
Under the Trump Rx plan, the administration outlined a series of proposed drug price changes across multiple companies and therapeutic areas. Among them were reductions for Amgen’s cholesterol-lowering drug repatha from $573 to $239; Bristol Myers Squibb’s HIV medication reyataz from $1,449 to $217; Boehringer Ingelheim’s type 2 diabetes medication jentadueto from $525 to $55; Genentech’s flu medication xofluza from $168 to $50; and Gilead Sciences’ hepatitis C medication epclusa from $24,920 to $2,425.
Additional reductions included several GSK inhalers — such as the asthma inhaler advair diskus 500/50, from $265 to $89 — Merck’s diabetes medication januvia from $330 to $100, Novartis’ multiple sclerosis medication mayzent from $9,987 to $1,137, and Sanofi’s blood thinner plavix from $756 to $16. Sanofi insulin products would also be capped at $35 per month’s supply.
These prices, however, would only be available to patients who purchase medications directly through TrumpRx. According to the program’s website, TrumpRx “connects patients directly with the best prices, increasing transparency, and cutting out costly third-party markups.”
Kennedy spoke after Trump, thanking the president for efforts to lower pharmaceutical costs in the U.S., where evidence has shown that drug prices — including both brand-name and generic medications — are nearly 2.78 times higher than prices in comparable countries. According to the Pharmaceutical Research and Manufacturers of America, roughly half of every dollar spent on brand-name drugs goes to entities that play no role in their research, development, or manufacturing.
“This is affordability in action,” Kennedy said. “We are reversing that trend and making sure that Americans can afford to get the life-saving solutions.”
Gilead CEO Dan O’Day also spoke about how the restructuring of drug costs under TrumpRx, combined with emerging technologies, could help reduce HIV transmission — a virus that, if untreated, can progress to AIDS. The LGBTQ community remains disproportionately affected by HIV.
“Thank you, Mr. President — you and the administration,” O’Day said. “I think this objective of achieving the commitment to affordability and future innovation is extraordinary … We just recently launched a new medicine that’s only given twice a year to prevent HIV, and we’re working with Secretary Kennedy and his entire team, as well as the State Department, as a part of your strategy to support ending the epidemic during your term.
“I’ve never been more optimistic about the innovation that exists across these companies and the impact this could have on America’s health and economy,” he added.
Trump interjected, asking, “And that’s working well with HIV?”
“Yes,” O’Day replied.
“It’s a big event,” Trump said.
“It literally prevents HIV almost 100 percent given twice a year,” O’Day responded.
A similar anti-HIV medication is currently prescribed more than injectable form mentioned by O’Day. PrEP, is a medication regimen proven to significantly reduce HIV infection rates for people at high risk. Without insurance, brand-name Truvada can cost roughly $2,000 per month, while a generic version costs about $60 per month.
Even when medication prices are reduced, PrEP access carries additional costs, including clinic and laboratory fees, office visits, required HIV and sexually transmitted infection testing, adherence services and counseling, and outreach to potentially eligible patients and providers.
According to a 2022 study, the annual total cost per person for PrEP — including medication and required clinical and laboratory monitoring — is approximately $12,000 to $13,000 per year.
The TrumpRx federal platform website is now live at TrumpRx.gov, but the program is not slated to begin offering reduced drug prices until January.
The White House
EXCLUSIVE: Democracy Forward files FOIA lawsuit after HHS deadnames Rachel Levine
Trans former assistant health secretary’s name changed on official portrait
Democracy Forward, a national legal organization that works to advance democracy and social progress through litigation, policy and public education, and regulatory engagement, filed a lawsuit Friday in federal court seeking to compel the U.S. Department of Health and Human Services to release information related to the alteration of former Assistant Secretary for Health Adm. Rachel Levine’s official portrait caption.
The lawsuit comes in response to the slow pace of HHS’s handling of multiple Freedom of Information Act requests — requests that federal law requires agencies to respond to within 20 working days. While responses can take longer due to backlogs, high request volumes, or the need for extensive searches or consultations, Democracy Forward says HHS has failed to provide any substantive response.
Democracy Forward’s four unanswered FOIA requests, and the subsequent lawsuit against HHS, come days after someone in the Trump-Vance administration changed Levine’s official portrait in the Hubert H. Humphrey Building to display her deadname — the name she used before transitioning and has not used since 2011.
According to Democracy Forward, HHS “refused to release any records related to its morally wrong and offensive effort to alter former Assistant Secretary for Health Admiral Rachel Levine’s official portrait caption.” Levine was the highest-ranking openly transgender government official in U.S. history and served as assistant secretary for health and as an admiral in the U.S. Public Health Service Commissioned Corps from 2021 to 2025.
Democracy Forward President Skye Perryman spoke about the need to hold the Trump-Vance administration accountable for every official action, especially those that harm some of the most targeted Americans, including trans people.
“The question every American should be asking remains: what is the Trump-Vance administration hiding? For an administration that touts its anti-transgender animus and behavior so publicly, its stonewalling and silence when it comes to the people’s right to see public records about who was behind this decision is deafening,” Perryman said.
“The government’s obligation of transparency doesn’t disappear because the information sought relates to a trailblazing former federal official who is transgender. It’s not complicated — the public is entitled to know who is making decisions — especially decisions that seek to alter facts and reality, erase the identity of a person, and affect the nation’s commitment to civil rights and human dignity.”
“HHS’s refusal to respond to these lawful requests raises more serious concerns about transparency and accountability,” Perryman added. “The public has every right to demand answers — to know who is behind this hateful act — and we are going to court to get them.”
The lawsuit also raises questions about whether the alteration violated federal accuracy and privacy requirements governing Levine’s name, and whether the agency improperly classified the change as an “excepted activity” during a lapse in appropriations. By failing to make any determination or produce any records, Democracy Forward argues, HHS has violated its obligations under federal law.
The case, Democracy Forward Foundation v. U.S. Department of Health and Human Services, was filed in the U.S. District Court for the District of Columbia. The legal team includes Anisha Hindocha, Daniel McGrath, and Robin Thurston.
The Washington Blade reached out to HHS, but has not received any comment.
The lawsuit and four FOIA requests are below:
‘Dogs of Venice’ looks at love lost and rediscovered
A Wider Bridge to close
‘Trump Rx’ plan includes sharp cuts to HIV drug prices
Rehoboth’s Blue Moon is for sale but owners aim to keep it in gay-friendly hands
Comings & Goings
LGBTQ Democrats say they’re ready to fight to win in 2026
Brian Footer suspends campaign for Ward 1 D.C. Council seat
Lighting candles in a time of exhaustion
Why queer spaces often fail South Asian women
